AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31521543 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency left sided rTMS (125 trains per day)
Number of subjects: 300
Study 31521543 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard left sided rTMS (50 trains per day)
Number of subjects: 300
Study 31521543 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard right sided rTMS (20 min per day)
Number of subjects: 300
Study 31521543 — intervention group
Group type: EXPERIMENTAL
Intervention: High right sided rTMS (60 min per day)
Number of subjects: 300
Study 31521543 — intervention group
Group type: EXPERIMENTAL
Intervention: High left sided treatment
Number of subjects: 300
Study 31521543 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 300
Study 30649163 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS-plus
Number of subjects: 750
Study 30649163 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Number of subjects: 750
Study 30649163 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 750
Study 27280511 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 505
Study 27280511 — intervention group
Group type: COMPARATOR
Intervention: Spleen preservation
Number of subjects: 505
Study 25455414 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/kg iodine load and 120 kVp tube voltage setting (600-120 group)
Number of subjects: 170
Study 25455414 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/kg iodine load and 80 kVp (500-80 group)
Number of subjects: 170
Study 25455414 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/kg iodine load and 80 kVp (400-80 group)
Number of subjects: 170
Study 25455414 — intervention group
Group type: COMPARATOR
Intervention: All groups (600-120, 500-80, 400-80)
Number of subjects: 170
Study 24332551 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic ACE scalpel (HS)
Number of subjects: 832
Study 24332551 — intervention group
Group type: COMPARATOR
Intervention: LigaSure Precise (LS) instrument
Number of subjects: 832
Study 23177745 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonant voice (RV) exercises
Number of subjects: 9
Study 23177745 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rest
Number of subjects: 9
Study 23177745 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous speech (SS)
Number of subjects: 9
Study 20009911 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (PCb)
Number of subjects: 607
Study 20009911 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 607
Study 20009911 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VC)
Number of subjects: 607
Study 17702881 — intervention group
Group type: EXPERIMENTAL
Intervention: PEPA intervention
Number of subjects: 48
Study 17702881 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48
Study 15165935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (endothelin receptor antagonist)
Number of subjects: 192
Study 15165935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 11524895 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment programs
Number of subjects: 0
Study 11524895 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement in therapy
Number of subjects: 0
Study 8986944 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged therapy group (5 MU tiw for a further 26 weeks)
Number of subjects: 310
Study 8986944 — intervention group
Group type: COMPARATOR
Intervention: Brief therapy group (stopped interferon)
Number of subjects: 310
Study 8986944 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged therapy group
Number of subjects: 310
Study 8986944 — intervention group
Group type: COMPARATOR
Intervention: Brief therapy group
Number of subjects: 310
Study 8986944 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sustained biochemical response
Number of subjects: 310
Study 8247317 — intervention group
Group type: EXPERIMENTAL
Intervention: tolrestat (aldose reductase inhibitor)
Number of subjects: 100
Study 8247317 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 3621990 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg spironolactone
Number of subjects: 63
Study 3621990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 27638453 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 374
Study 27638453 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 374
Study 26725101 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 44
Study 26725101 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 44
Study 24916511 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 240
Study 21544086 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week dietary intervention
Number of subjects: 80
Study 21544086 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week dietary intervention (A142V polymorphism CC and CT group)
Number of subjects: 80
Study 21544086 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week dietary intervention (R65L polymorphism GG and GT group)
Number of subjects: 80
Study 21544086 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (control group)
Number of subjects: 80
Study 20536757 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling for patients after surgery
Number of subjects: 174
Study 18178011 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Interactive Voice Response (TIVR) for 4 months
Number of subjects: 51
Study 18178011 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (Control)
Number of subjects: 51
Study 16686000 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic needle placement for radio-frequency ablation
Number of subjects: 0
Study 16686000 — intervention group
Group type: COMPARATOR
Intervention: Manual needle placement for radio-frequency ablation
Number of subjects: 0
Study 12514146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2% with propofol 2 mg x kg(‐1) (Group I)
Number of subjects: 45
Study 12514146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% (Group II)
Number of subjects: 45
Study 12514146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with gradual reduction technique (8, 6, 4% for each minute) (Group III)
Number of subjects: 45
Study 10393599 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 to 10 puffs of albuterol via MDI with spacer (n = 30)
Number of subjects: 90
Study 10393599 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 puffs of albuterol via MDI with spacer (n = 30)
Number of subjects: 90
Study 10393599 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of albuterol via nebulizer (n = 30)
Number of subjects: 90
Study 9715320 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with antibiotics
Number of subjects: 104
Study 9715320 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in storage time
Number of subjects: 104
Study 9715320 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl thiazol tetrazolium (MTT) assay
Number of subjects: 104
Study 9715320 — intervention group
Group type: COMPARATOR
Intervention: Basal media with and without nutrients (DMEM and Hanks BSS)
Number of subjects: 104
Study 1560152 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine HCl 4%
Number of subjects: 11
Study 1560152 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine HCl 4% with epinephrine 1:50,000
Number of subjects: 11
Study 1560152 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study 2865145 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg eight-hourly
Number of subjects: 224
Study 2865145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 29722627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot supplementation
Number of subjects: 9
Study 29722627 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-poor (placebo) beetroot supplementation
Number of subjects: 9
Study 27491658 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard procedure with balloon predilatation
Number of subjects: 60
Study 27491658 — intervention group
Group type: COMPARATOR
Intervention: Omitted balloon predilatation
Number of subjects: 60
Study 26047635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 16
Study 26047635 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 16
Study 23611518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified regimen of enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 128
Study 23611518 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 128
Study 21044299 — intervention group
Group type: EXPERIMENTAL
Intervention: COPCA (Coping with and Caring for infants with special needs ‐ a family centered program)
Number of subjects: 0
Study 21044299 — intervention group
Group type: COMPARATOR
Intervention: Traditional infant physiotherapy
Number of subjects: 0
Study 19317161 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Wenyang Huoxue Recipe (YWHR) given daily for 10 days
Number of subjects: 60
Study 19317161 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Wenyang Huoxue Recipe (YWHR)
Number of subjects: 60
Study 16640636 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil system (G3)
Number of subjects: 60
Study 16640636 — intervention group
Group type: COMPARATOR
Intervention: System B (G2)
Number of subjects: 60
Study 16640636 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation (G1)
Number of subjects: 60
Study 14502777 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (BCT)
Number of subjects: 928
Study 14502777 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy (Mx)
Number of subjects: 928
Study 10850507 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin (0.1 mg/kg, administered within the first 24 hours of life, repeated every 24 hours for 6 doses)
Number of subjects: 90
Study 10850507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered within the first 24 hours of life, repeated every 24 hours for 6 doses)
Number of subjects: 90
Study 8791036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 55
Study 8791036 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine 150 mg/day
Number of subjects: 55
Study 1361781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 25 mg/l during four short dwell exchanges (dwell time 1.5 h)
Number of subjects: 6
Study 1361781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg/l in the last-bag
Number of subjects: 6
Study 1361781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 25 mg/l in the last-bag
Number of subjects: 6
Study 1361781 — intervention group
Group type: COMPARATOR
Intervention: No ciprofloxacin during four subsequent 1.5h exchanges
Number of subjects: 6
Study 6368563 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative repair
Number of subjects: 100
Study 6368563 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment in a plaster cast
Number of subjects: 100
Study 31494621 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (specific type and dosage not mentioned)
Number of subjects: 0
Study 31494621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29214507 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin once daily
Number of subjects: 312
Study 29214507 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin twice daily
Number of subjects: 312
Study 26421801 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 125
Study 26421801 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 125
Study 24689456 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten (16 g/day)
Number of subjects: 22
Study 24689456 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey (16 g/day)
Number of subjects: 22
Study 24689456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not supplemented)
Number of subjects: 22
Study 22318363 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic lenses producing a deviation of 5 degrees to the right
Number of subjects: 29
Study 22318363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pointing exercises
Number of subjects: 29
Study 22318363 — intervention group
Group type: COMPARATOR
Intervention: Neutral lenses (placebo)
Number of subjects: 29
Study 20624011 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg p.o. bi-daily for 4 months)
Number of subjects: 22
Study 17711996 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 with placebo
Number of subjects: 29
Study 17711996 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 with glyburide
Number of subjects: 29
Study 17711996 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 with glimepiride
Number of subjects: 29
Study 16291352 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway for management of bronchiolitis
Number of subjects: 436
Study 12400431 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and oral administration of Huo Xue Ming Mu Decoction
Number of subjects: 32
Study 9952267 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 184
Study 9952267 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) monotherapy
Number of subjects: 184
Study 9952267 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytherapy (more than one AED)
Number of subjects: 184
Study 9952267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 9952267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (VPA)
Number of subjects: 184
Study 9952267 — intervention group
Group type: COMPARATOR
Intervention: Sexuality Experience Scores (SES)
Number of subjects: 184
Study 8649918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 degree rotation
Number of subjects: 17
Study 8649918 — intervention group
Group type: EXPERIMENTAL
Intervention: randomized neck rotation positions
Number of subjects: 17
Study 1857134 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 6407052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusaric acid plus L-dopa
Number of subjects: 0
Study 6407052 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa alone
Number of subjects: 0
Study 6407052 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 6407052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30403402 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil extended-release (GE-XR) 600 mg twice a day
Number of subjects: 346
Study 30403402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 29729860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory therapy combined with exercise training (V+ET)
Number of subjects: 118
Study 29729860 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone (ET)
Number of subjects: 118
Study 29729860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory therapy combined with exercise training (V+ET) in subjects with central sleep apnoea (CSA)
Number of subjects: 118
Study 29729860 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone (ET) in subjects with central sleep apnoea (CSA)
Number of subjects: 118
Study 29729860 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone (ET) in subjects with obstructive sleep apnoea (OSA)
Number of subjects: 118
Study 29729860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory therapy combined with exercise training (V+ET) in subjects with obstructive sleep apnoea (OSA)
Number of subjects: 118
Study 27103201 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-binding protein
Number of subjects: 333
Study 27103201 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25-OH D)
Number of subjects: 333
Study 24509716 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PET/CT imaging
Number of subjects: 99
Study 24509716 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and 6-week PET/CT imaging
Number of subjects: 99
Study 24509716 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and 12-week PET/CT imaging
Number of subjects: 99
Study 22228539 — intervention group
Group type: COMPARATOR
Intervention: 453 g concentrate (T1)
Number of subjects: 30
Study 22228539 — intervention group
Group type: EXPERIMENTAL
Intervention: 342 g concentrate + 74 g lupin seed (T2)
Number of subjects: 30
Study 22228539 — intervention group
Group type: EXPERIMENTAL
Intervention: 228 g concentrate + 147 g lupin seed (T3)
Number of subjects: 30
Study 22228539 — intervention group
Group type: EXPERIMENTAL
Intervention: 116 g concentrate + 219 g lupin seed (T4)
Number of subjects: 30
Study 22228539 — intervention group
Group type: EXPERIMENTAL
Intervention: 290 g lupin seed (T5)
Number of subjects: 30
Study 19737630 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased GI (iGI) variants
Number of subjects: 40
Study 19737630 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased GI (dGI) variants
Number of subjects: 40
Study 19737630 — intervention group
Group type: COMPARATOR
Intervention: Reference solution (glucose solution)
Number of subjects: 40
Study 17517820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (specific medications not detailed)
Number of subjects: 415
Study 17517820 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 415
Study 17517820 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 415
Study 17517820 — intervention group
Group type: COMPARATOR
Intervention: No pharmacotherapy (Control)
Number of subjects: 415
Study 16390022 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc(V)-DMSA scan
Number of subjects: 28
Study 16390022 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-MDP scan
Number of subjects: 28
Study 16390022 — intervention group
Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 28
Study 12589270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedal unit position behind the saddle axis
Number of subjects: 10
Study 12589270 — intervention group
Group type: COMPARATOR
Intervention: Pedal unit position in front of the saddle axis
Number of subjects: 10
Study 10604698 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch retropubic urethropexy
Number of subjects: 289
Study 10604698 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pereyra procedure
Number of subjects: 289
Study 10604698 — intervention group
Group type: COMPARATOR
Intervention: Anterior repair
Number of subjects: 289
Study 8540119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin high dose (100 mg/m2 i.v. day 1) + Etoposide (100 mg/m2 i.v. days 4, 6, and 8)
Number of subjects: 95
Study 8540119 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin low dose (60 mg/m2 day 1) + Etoposide (100 mg/m2 i.v. days 4, 6, and 8)
Number of subjects: 95
Study 8540119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin high dose (100 mg/m2 i.v. day 1)
Number of subjects: 95
Study 8540119 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin low dose (60 mg/m2 day 1)
Number of subjects: 95
Study 2312831 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF-30 sunscreen
Number of subjects: 0
Study 2312831 — intervention group
Group type: COMPARATOR
Intervention: SPF-15 sunscreen
Number of subjects: 0
Study 7002357 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 7002357 — intervention group
Group type: COMPARATOR
Intervention: Sulfinpyrazone
Number of subjects: 0
Study 30428398 — intervention group
Group type: COMPARATOR
Intervention: PCI with sirolimus-eluting or paclitaxel-eluting stents
Number of subjects: 943
Study 30428398 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 943
Study 27809622 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus isosorbide mononitrate 10 mg vaginal tablets
Number of subjects: 120
Study 27809622 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg daily plus placebo vaginal tablets
Number of subjects: 120
Study 25165161 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV) followed by Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 39
Study 25165161 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV) followed by Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 39
Study 25165161 — intervention group
Group type: COMPARATOR
Intervention: Initial dose of Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 39
Study 25165161 — intervention group
Group type: COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV)
Number of subjects: 39
Study 25165161 — intervention group
Group type: COMPARATOR
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 39
Study 24991557 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-mediated exercise (FME)
Number of subjects: 20
Study 24991557 — intervention group
Group type: COMPARATOR
Intervention: No-feedback exercise (NFE)
Number of subjects: 20
Study 22130166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0
Study 22130166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and vaccine
Number of subjects: 0
Study 19625327 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for mixed urinary incontinence (MUI)
Number of subjects: 27
Study 19625327 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment for mixed urinary incontinence (MUI)
Number of subjects: 27
Study 17565782 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with wild representation (monkey or clothed dog)
Number of subjects: 0
Study 17565782 — intervention group
Group type: COMPARATOR
Intervention: Control group (Gadje majority)
Number of subjects: 0